Cost of antipsychotic polypharmacy in the treatment of schizophrenia

Zhu, Baojin; Ascher-Svanum, Haya; Faries, Douglas E.; Correll, Christoph U.; Kane, John M.
January 2008
BMC Psychiatry;2008, Vol. 8, Special section p1
Academic Journal
Background: This study compared the costs of antipsychotic polypharmacy for patients who initiated on 1 of the 3 most commonly prescribed atypical antipsychotics -- olanzapine, quetiapine, or risperidone. Methods: Data were drawn from a large, prospective, naturalistic, multi-site, nonrandomized study of treatment for schizophrenia in the United States conducted between July 1997 and September 2003. Participants who were initiated on olanzapine (N = 405), quetiapine (N = 115), or risperidone (N = 276) were followed for 1 year post initiation and compared on: (a) average daily cost of the index antipsychotic while on the index antipsychotic, (b) average daily cost of the coprescribed antipsychotics while on the index antipsychotic, (c) average daily cost of the index antipsychotic and the coprescribed antipsychotics while on the index antipsychotic, (d) total annual cost of antipsychotic medications prescribed in the year following initiation on the index antipsychotic, using propensity score-adjusted bootstrap resampling method. Average daily antipsychotic costs and total annual antipsychotic costs were also estimated using more recent (2004) antipsychotic drug prices. Results: During the 1 year following initiation on the index antipsychotic, the total average daily cost of the index antipsychotic was higher for quetiapine ($15.33) than olanzapine ($13.90, p < .05) and risperidone ($11.04, p < .01), although the average daily cost of the index antipsychotic was higher for olanzapine ($10.08) than risperidone ($6.74, p < .01) or quetiapine ($6.63, p < .01). Lower total average daily costs were observed in risperidone than olanzapine or quetiapine. Significantly lower average daily cost of concomitant antipsychotic medications for olanzapine ($3.82) compared to quetiapine ($8.70, p < .01) or risperidone-initiated patients ($4.30, p < .01) contributed to the lower average daily cost of all antipsychotic medication for olanzapine-initiated patients. Each dollar spent on the index antipsychotic was accompanied by spending an additional $1.31 on concomitant antipsychotics for quetiapine compared to $0.64 for risperidone and $0.38 for olanzapine-initiated patients. A separate intent-to-treat analysis of the total annual antipsychotic cost found a significantly higher total annual antipsychotic cost for quetiapine-initiated patients ($5320) compared to olanzapine ($4536, p < .01) or risperidone ($3813, p < .01). Conclusion: Prevalent antipsychotic polypharmacy adds substantial cost to the treatment of schizophrenia. Comparison of medication costs need to address the costs of all antipsychotics. A better understanding of concomitant antipsychotic costs provides a more accurate portrayal of antipsychotic medication costs in the treatment of schizophrenia.


Related Articles

  • Cost analysis of schizophrenia treatment with second-generation antipsychotic medications in North Carolina's Medicaid program. Liu, Gordon G.; Sun, Shawn X.; Christensen, Dale B.; Zhongyun Zhao; Zhao, Zhongyun // Journal of the American Pharmacists Association: JAPhA;Jan/Feb2007, Vol. 47 Issue 1, p77 

    The article discusses the results of a cost analysis of schizophrenia treatment with second-generation antipsychotic medications in the Medicaid program of North Carolina. It showed that olanzapine costs more than risperidone in terms of drug expenditures but is associated with lower use of...

  • Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia. Yu, Wei; Ren, Xinhua S.; Lee, Austin F.; Herz, Lawrence; Huang, Yu-Hui; Kazis, Lewis E. // PharmacoEconomics;2006, Vol. 24 Issue 12, p1233 

    BACKGROUND: Olanzapine and risperidone are two commonly prescribed atypical antipsychotics for schizophrenia. Prior studies have shown inconsistent results in terms of advantage in cost saving in prescribing these agents. Our preliminary analysis showed that a small percentage of intensive...

  • Comparing the Cost Effectiveness of Risperidone and Olanzapine in the Treatment of Schizophrenia Using the Net-Benefit Regression Approach. de Ridder, Annemieke; de Graeve, Diana // PharmacoEconomics;2009, Vol. 27 Issue 1, p69 

    Objective: To estimate the cost effectiveness of olanzapine and risperidone for the treatment of schizophrenia in Belgium. Methods: Data were retrieved from a prospective, observational, nonrandomized, follow-up survey. Clinical investigators assigned 265 patients with schizophrenia to either...

  • The promise of new drugs for schizophrenia treatment. Tamminga, C. A.; Tamminga, Ca // Canadian Journal of Psychiatry;Apr1997, Vol. 42 Issue 3, p265 

    Objective: To present aspects of preclinical and clinical pharmacology of new antipsychotic drugs and to emphasize those preclinical drug characteristics which might predict desirable clinical actions.Method: Review of the relevant literature and publicly presented...

  • Economic evaluations of olanzapine and risperidone. Shaw, James W. // American Journal of Health-System Pharmacy;7/15/2002, Vol. 59 Issue 14, p1366 

    Presents an economic analysis comparing olanzapine and risperidone for treating schizophrenia. Overview of the disease; Costs of schizophrenia; Methods of economic evaluation; Results of randomized clinical trials.

  • Medication Treatment Patterns following Initiation on Olanzapine versus Risperidone: A Retrospective Analysis. Zhao, Z.; Tunis, S.L.; Lage, M.J. // Clinical Drug Investigation;2002, Vol. 22 Issue 11, p741 

    Objective: To compare medication treatment patterns for patients with schizophrenia following initiation on olanzapine versus risperidone. Methods: Retrospective analysis of a large, geographically diverse claims database of insured individuals identified 670 enrollees who: (1) were diagnosed...

  • A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia. Fitzgerald, Paul B.; Brown, Timothy L.; Daskalakis, Jeff Z.; Kulkarni, J. // Psychopharmacology;2002, Vol. 162 Issue 1, p74 

    Rationale: There has been a progressive increase in interest in the functioning of the main inhibitory and excitatory neurotransmitters in the pathophysiology of schizophrenia. Limited information is available as to how these neurotransmitters are affected by commonly prescribed antipsychotic...

  • Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia. Edgell, E.T.; Andersen, S.W.; Johnstone, B.M.; Dulisse, B.; Revicki, D.; Breier, A. // PharmacoEconomics;2000, Vol. 18 Issue 6, p567 

    Objective: To compare the clinical and economic outcomes associated with olanzapine and risperidone treatment for schizophrenia.Design and Setting: An international, multicentre, double-blind, prospective study. To facilitate economic comparisons, our sample was...

  • Treatment Refractory Schizophrenia. Lindemayer, Jean-Pierre // Psychiatric Quarterly;Dec2000, Vol. 71 Issue 4, p373 

    Treatment resistance constitutes a significant dilemma in schizophrenia since it affects a substantial number of patients, their families and the health care professionals involved in their care. Nonresponsiveness needs to be approached as a multidimensional syndrome by specifying which symptoms...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics